Bristol Myers to buy RayzeBio for about $4.1B

Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second large deal struck by the drugmaker in less than a week. With the deal, Bristol will gain access to RayzeBio's late-stage targeted cancer therapy, RYZ101, which works by combining radioactive particles that kill cells with molecules that attach themselves to the tumors.The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlim ...